CLAIMS

1. A compound of formula (I):



(I)

wherein

A and B represent the groups $-(CH_2)_m-$ and $-(CH_2)_n-$ respectively;

R^1 represents C_{1-6}alkyl;

R^2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC_{1-6}alkyl, trifluoromethyl, trifluoromethoxy, C_{1-6}alkyl, C_{1-6}alkoxy, $-(CH_2)_pC_{3-6}$cycloalkyl, $-(CH_2)_pOC_{3-6}$cycloalkyl, $-COC_{1-6}$alkyl, $-SO_2C_{1-6}$alkyl, $-SOC_{1-6}$alkyl, $-S-C_{1-6}$alkyl, $-CO_2C_{1-6}$alkyl, $-CO_2NR^4R^5$, $-SO_2NR^4R^5$, $-(CH_2)_pNR^4R^5$, $-(CH_2)_pNR^4COR^5$, an optionally substituted aryl group, an optionally substituted heteroaryl group or an optionally substituted heterocyclyl group;

R^3 represents hydrogen or C_{1-6}alkyl;

Ar^1 represents an optionally substituted heteroaryl group;

Ar^2 represents an optionally substituted phenyl or an optionally substituted heteroaryl group;

Y represents a bond, -O-, $-C_{1-6}$alkyl-, $-CR^6R^7X-$, $-XCR^6R^7-$, $-NR^8CO-$ or $-CONR^8-$;

X represents oxygen, sulfur, -SO- or $-SO_2-$;

R^4 and R^5 each independently represent hydrogen or C_{1-6}alkyl or, together with the nitrogen or other atoms to which they are attached, form an azacycloalkyl ring or an oxo-substituted azacycloalkyl ring;

R^6 and R^7 each independently represent hydrogen, C_{1-6}alkyl or fluoro;

R^8 represents hydrogen or C_{1-6}alkyl;

m and n independently represent an integer selected from 1 and 2;

p independently represents an integer selected from 0, 1, 2 and 3;

or a pharmaceutically acceptable salt, solvate or pharmaceutically acceptable derivative thereof.

2. A compound of formula (I) which is

5-(4-Chlorophenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;

5-(3-Methoxyphenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;

5-(4-Methoxyphenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;

5-(3,4-Difluorophenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;

5-(2,4-Difluorophenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;
5-(3-Chlorophenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;
5-(3-Fluorophenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;
5-(4-Trifluoromethylphenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;
5-(3-Trifluoromethylphenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;
5-(4-Fluorophenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;
5-(4-Fluorophenyl)-thiophene-2-sulfonic acid (3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;
5-(4-Chlorophenyl)-thiophene-2-sulfonic acid (3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;
5-(4-Chloro-2-methylphenyl)-thiophene-2-sulfonic acid (2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)-amide;
5-Isoxazol-3-yl-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)-amide;
5-(2-Methylthiazol-5-yl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)-amide;
[2,3']Bithiophenyl-5-sulfonic acid (2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amide;
[2,3']Bithiophenyl-5-sulfonic acid (3-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amide;
5-(4-Chlorophenyl)thiophene-2-sulfonic acid (8-dimethylamino-3-methyl-2,3,4,5-tetrahydro-*1H*-3-benzazepin-7-yl)amide;
5-(4-Fluorophenyl)thiophene-2-sulfonic acid (8-dimethylamino-3-methyl-2,3,4,5-tetrahydro-*1H*-3-benzazepin-7-yl)amide;
5-(2,4-Difluorophenyl)thiophene-2-sulfonic acid (8-dimethylamino-3-methyl-2,3,4,5-tetrahydro-*1H*-3-benzazepin-7-yl)amide; and
5-(3,4-Difluorophenyl)thiophene-2-sulfonic acid (8-dimethylamino-3-methyl-2,3,4,5-tetrahydro-*1H*-3-benzazepin-7-yl)amide.

3. A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 1 or claim 2 or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier therefor.

4. Use of a compound of formula (I) according to claim 1 or claim 2 or a pharmaceutically acceptable derivative thereof in therapy.

5. Use of a compound of formula (I) according to claim 1 or claim 2 for the treatment of a condition which requires modulation of a dopamine receptor.

6. Use of a compound of formula (I) according to claim 5 wherein the condition is schizophrenia or substance abuse.

7. Use of a compound of formula (I) according to claim 1 or claim 2 in the manufacture of a medicament for the treatment of a condition which requires modulation of a dopamine receptor.

8. Use of a compound of formula (I) according to claim 7 wherein the condition is schizophrenia or substance abuse.

9. A method of treating a condition which requires modulation of dopamine receptors which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) according to claim 1 or claim 2.

10. A method of treating a condition according to claim 9 wherein the condition is schizophrenia or substance abuse.